These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 23819752)

  • 1. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins in cardiometabolic disease: what makes pitavastatin different?
    Ginsberg H
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin diabetogenicity: guidance for clinicians.
    Ray K
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin and HDL: Effects on plasma levels and function(s).
    Pirillo A; Catapano AL
    Atheroscler Suppl; 2017 Jul; 27():e1-e9. PubMed ID: 28716185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
    Saito Y
    Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
    Duggan ST
    Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J; Shao Y; Liu Y; Tao J
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
    Nakajima K
    Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.